NorthRock Partners LLC Purchases 243 Shares of DexCom, Inc. (NASDAQ:DXCM)

NorthRock Partners LLC grew its position in shares of DexCom, Inc. (NASDAQ:DXCMFree Report) by 8.6% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 3,071 shares of the medical device company’s stock after buying an additional 243 shares during the quarter. NorthRock Partners LLC’s holdings in DexCom were worth $381,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Valley National Advisers Inc. grew its holdings in DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after acquiring an additional 103 shares during the last quarter. MV Capital Management Inc. increased its holdings in shares of DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 138 shares in the last quarter. Smithfield Trust Co raised its position in DexCom by 103.1% in the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after purchasing an additional 165 shares during the last quarter. Washington Trust Advisors Inc. boosted its holdings in DexCom by 120.6% in the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock valued at $44,000 after acquiring an additional 193 shares during the last quarter. Finally, NBC Securities Inc. acquired a new stake in DexCom in the third quarter worth about $47,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Down 0.4 %

NASDAQ DXCM traded down $0.55 during trading hours on Friday, hitting $131.36. 2,329,399 shares of the company traded hands, compared to its average volume of 2,690,321. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00. The stock has a market capitalization of $52.24 billion, a price-to-earnings ratio of 84.75, a P/E/G ratio of 2.25 and a beta of 1.23. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The business’s 50-day moving average is $133.26 and its 200-day moving average is $123.00.

DexCom (NASDAQ:DXCMGet Free Report) last posted its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The business had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. Sell-side analysts anticipate that DexCom, Inc. will post 1.78 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. UBS Group raised their target price on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Citigroup lifted their target price on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. StockNews.com upgraded DexCom from a “hold” rating to a “buy” rating in a research report on Friday. Raymond James upped their price objective on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Finally, Canaccord Genuity Group raised their target price on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $141.67.

Get Our Latest Analysis on DexCom

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 14,639 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total value of $1,967,627.99. Following the transaction, the chief operating officer now directly owns 273,913 shares of the company’s stock, valued at approximately $36,816,646.33. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CFO Jereme M. Sylvain sold 3,363 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the transaction, the chief financial officer now directly owns 71,142 shares of the company’s stock, valued at $8,304,405.66. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 14,639 shares of the business’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the completion of the sale, the chief operating officer now directly owns 273,913 shares of the company’s stock, valued at approximately $36,816,646.33. The disclosure for this sale can be found here. Insiders sold 190,004 shares of company stock valued at $25,610,270 in the last quarter. 0.30% of the stock is currently owned by insiders.

DexCom Company Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Recommended Stories

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMFree Report).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.